Navigation Links
Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
Date:12/16/2009

EVANSTON, Ill., Dec. 16 /PRNewswire/ -- Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study. GLYX-13, a glycine site functional partial agonist (GFPA) selective modulator of the NMDA receptor, is initially being developed as a therapy for treatment-resistant depression in severely depressed patients admitted to the hospital. Separately, Naurex announced that data presented at a recent medical meeting reported that GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity in animal models with no signs of the CNS-related side effects observed with other drugs targeting the NMDA receptor. The studies also showed that the antidepressant effects of GLYX-13 were evident within 20 minutes and demonstrated a lasting antidepressant effect of greater than four days after administration of a single dose. In these studies, GLYX-13 affected both the positive and negative symptoms of depression.

"Based on its demonstrated safety and antidepressant-like activity in well-validated animal models, we are pleased to have begun assessing GLYX-13 in human trials," said Ronald Burch, MD, PhD, chief medical officer at Naurex. "We are optimistic that this Phase I safety trial will pave the way for rapidly proceeding to more advanced trials in patients admitted to the hospital with severe treatment-resistant depression, a condition with an urgent need for additional treatment options."

The GLYX-13 Phase I trial is a randomized, double-blind, placebo-controlled single ascending dose level study of the safety, tolerability and pharmacokinetics of GLYX-13. The trial is currently recruiting and plans to enroll 20 healthy volunteers. The primary outcome measure is o
'/>"/>

SOURCE Naurex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
2. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
3. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
4. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
5. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
6. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
7. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
8. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
9. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
10. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
11. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  This industry report package offers the most ... for safety glass in the world and in the top 10 global ... country reports from the following countries: Australia ... Germany , Italy , Japan ... United Kingdom , United States ...
(Date:3/3/2015)... March 3, 2015  UnaliWear announces the market preview ... for seniors that guards against wandering and provides support ... new wearable – the Kanega watch ( http://www.UnaliWear.com ) ... use an easy speech interface rather than buttons, use ... human input. The watch goes wherever ...
(Date:3/3/2015)... 3, 2015  Columbia Laboratories, Inc. (Nasdaq: ... Company"), a specialty pharmaceutical company focused on pharmaceuticals for ... the 27th Annual ROTH Conference, which will take place ... Dana Point, California . Management,s presentation ... a.m. Pacific Time (12:00 p.m. Eastern Time) in the ...
Breaking Medicine Technology:Global Safety Glass Market to 2019 - Market Size, Top 10 Countries, Trends, and Forecasts 2UnaliWear's Wearable For Seniors Extends Independence With Advanced Technology 2
... BANGALORE, KARNATAKA, India, Oct. 19 Cardiac Science Corporation (Nasdaq: ... Code: 532391; NSE: OPTOCIRCUI] today announced they have entered into ... to acquire all of the outstanding shares of Cardiac Science ... represents a 10% premium to the closing price of Cardiac ...
... SAN DIEGO, Oct. 18 Althea Technologies, Inc., ... for biopharmaceuticals and parenteral drug products, announced today ... new INOVA H3-5 high-speed syringe filling line.  This ... commercial manufacturing facility in San Diego. The expanded ...
Cached Medicine Technology:Opto Circuits to Acquire Cardiac Science 2Opto Circuits to Acquire Cardiac Science 3Opto Circuits to Acquire Cardiac Science 4Opto Circuits to Acquire Cardiac Science 5Opto Circuits to Acquire Cardiac Science 6Opto Circuits to Acquire Cardiac Science 7Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line 2
(Date:3/3/2015)... (PRWEB) March 03, 2015 On February ... complaint in the United States District Court for the ... Financial Freedom, as well as insurance companies Balboa, QBE, ... 2015 in Case No. 3:14-cv-152.) , The Plaintiff, a ... insurance companies to force her to buy too much ...
(Date:3/3/2015)... 2015 Longtime parent visionary and inspiring ... Surrogacy Center for a candid interview on the ... is an exhilarating revelation of his magical surrogacy journey ... from Australia to the birth of his precious twin ... Umar, CEO and Founder of CARE stated, “We are ...
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles ... crimes, recently spoke on the radio to give his insights ... the Independent Journal Review radio show “The Right Mics” chose ... prosecutor and now as a criminal defense attorney would provide ... trial and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... (PRWEB) March 04, 2015 The report ... on the therapeutic development for Alopecia. Alopecia is the ... the two main types of alopecia. Causes for alopecia ... Symptoms of alopecia may include male pattern hair loss, ... hair. Alopecia can be classified as focal or diffuse ...
(Date:3/3/2015)... 2015 The first week of March ... Foundation. The event brings recognition to a rarely discussed ... According to the Centers for Disease Control , ... form or another. Too little or unrestful sleep is ... illness and depression, and even a higher likelihood of ...
Breaking Medicine News(10 mins):Health News:Borrower Accuses Mortgage Lenders of Racketeering in Forcing Insurance on Homeowners 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 3Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3
... ... tobacco, MINNEAPOLIS, Nov. 14 ... Begun in Monticello,Minnesota, and now supported nationwide by the American Cancer Society, ... "The Great American Smokeout is rooted in Minnesota, so it,s fitting,that ...
... asthma patients avoid fracture, researchers say , , WEDNESDAY, ... has proven superior to standard therapy at slowing ... , Glucocorticoid medicines such as prednisone are often ... and other conditions, researchers note. But the drugs ...
... College of Wisconsin in Milwaukee have found that the ... may be reduced by a drug in common use. ... issue of the International Journal of Radiation Oncology, Biology ... the drug captopril, starting at three weeks after patients ...
... added survival remains unclear, scientists say , , WEDNESDAY, Nov. ... live longer following an Alzheimer,s diagnosis than white patients, ... of Asian and American Indian descent diagnosed with the ... that of white Alzheimer,s patients, patients of Hispanic ...
... Community Hospital of Long Beach (CHLB) is entering to win a ... The hospital that receives the most ... scanner. Voting is taking place NOW through December 31, ... select ,Community Hospital of Long ...
... Dynatronics,Corporation (Nasdaq: DYNT ) will release financial results ... of Monday, November 19, 2007.,The Company filed an extension ... statements due to the six acquisitions that were,made on ... has scheduled a conference call for investors at 1:30 ...
Cached Medicine News:Health News:ClearWay Minnesota(SM) to Share Stories of Real Minnesotans Who Used QUITPLAN(R) Services During Great American Smokeout 2Health News:New Drug Fights Medication-Linked Bone Loss 2Health News:Medical College of Wisconsin study finds drug may limit radiation kidney damage in BMT patients 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 3Health News:Blacks, Hispanics Live Longer With Alzheimer's 4Health News:Community Hospital of Long Beach - Help Us Win an MRI Scanner! 2
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Castroviejo tying forceps, straight....
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures....
Tennant stainless steel tying forceps is extra delicate, straight with smooth jaws, 6 mm long platform, round handle with guide pin. For 9-0 to 11-0 sutures....
Medicine Products: